WTAP enhances bladder cancer cell survival and suppresses erastin-driven ferroptosis by promoting methylation of a critical m6A site in the nuclear factor erythroid 2-related factor 2 (NRF2) mRNA 3'-UTR, which is subsequently stabilized via YTHDF1-mediated recognition of this modification [66]. The gene discussed is NFE2L2; the disease is urinary bladder carcinoma.